Log in
OTCMKTS:PHMMF

Pharma Mar Stock Forecast, Price & News

$124.45
0.00 (0.00 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$124.45
Now: $124.45
$124.45
50-Day Range
$92.30
MA: $125.12
$156.00
52-Week Range
$23.40
Now: $124.45
$158.75
Volume1 shs
Average Volume188 shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.
Read More
Pharma Mar logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PHMMF
Previous SymbolNASDAQ:PHMMF
CUSIPN/A
CIKN/A
Phone34-91-846-6000
Employees487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.12 million
Book Value$0.45 per share

Profitability

Miscellaneous

Market Cap$2.29 billion
Next Earnings DateN/A
OptionableNot Optionable
$124.45
0.00 (0.00 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHMMF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharma Mar (OTCMKTS:PHMMF) Frequently Asked Questions

How has Pharma Mar's stock price been impacted by COVID-19?

Pharma Mar's stock was trading at $3.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PHMMF shares have increased by 3,455.7% and is now trading at $124.45.
View which stocks have been most impacted by COVID-19
.

Who are some of Pharma Mar's key competitors?

Who are Pharma Mar's key executives?

Pharma Mar's management team includes the following people:
  • Mr. José María Fernández Sousa-Faro, Founder, Exec. Chairman, CEO & Pres
  • Mr. Pedro Francisco Fernández Puentes, Exec. Vice-Chairman
  • Mr. Juan Carlos-Torres Carretero, Founder (Age 71)
  • Ms. María Luisa de Francia Caballero, Chief Financial Officer
  • Mr. Pascal Besman, Chief Operating Officer

What is Pharma Mar's stock symbol?

Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."

How do I buy shares of Pharma Mar?

Shares of PHMMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pharma Mar's stock price today?

One share of PHMMF stock can currently be purchased for approximately $124.45.

How big of a company is Pharma Mar?

Pharma Mar has a market capitalization of $2.29 billion and generates $96.12 million in revenue each year. The company earns $-12,740,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Pharma Mar employs 487 workers across the globe.

What is Pharma Mar's official website?

The official website for Pharma Mar is www.pharmamar.com.

How can I contact Pharma Mar?

Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The company can be reached via phone at 34-91-846-6000 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.